What Does the Historical and Current Conjugate Vaccine Market Size Trend Indicate?
The conjugate vaccine market has seen considerable growth due to a variety of factors.
•The market size for conjugate vaccines has seen a swift uptick in the past few years. It is set to rise from a worth of $18.9 billion in 2024 to approximately $21.46 billion in 2025, indicating a compound annual growth rate (CAGR) of 13.5%.
The remarkable growth during the historic period can be associated with factors such as disease load, state-led immunization initiatives, heightened awareness, focus on pediatric vaccination, and trends in preventive healthcare.
How Will the Conjugate Vaccine Market Size Evolve over the Forecast Period?
The conjugate vaccine market is expected to maintain its strong growth trajectory in upcoming years.
• The conjugate vaccine industry's size is set for a swift expansion in the coming years, predicted to reach "$34.59 billion by 2029, with a compound annual growth rate (CAGR) of 12.7%.
The surge during the forecast period could be driven by broader immunization policies, changing demographics of aging populations, new indications for vaccines, worldwide health safety issues, international co-operation, and economic development influence. Notable trends during the forecast period encompass collaborations and partnerships for vaccine distribution, customized strategies for high-risk groups, use in combating emerging infectious diseases, advancement in vaccine production technologies, and worldwide health campaigns for equal access to vaccines.
Which Factors Are Boosting Growth In The Conjugate Vaccine Market?
The surge in conjugate vaccines usage among adults is predicted to fuel the conjugate vaccine market's expansion. These vaccines are designed to initiate a powerful immune response to bacterial capsular polysaccharides, thereby bolstering the body's resistance to bacterial infections. Using conjugate vaccines in adults can minimize the severity of diseases, complications, and transmission stimulated by a potent immune response. For instance, based on the June 2024 reports from the UK Health Security Agency (UKHSA), a public health agency in the UK, the 12-month coverage for the '6-in-1' vaccine remained stable at 91.7% in the UK. The initial dose of the pneumococcal conjugate vaccine (PCV) continued at 93.7%. The coverage for rotavirus saw a slight increase of 0.6%, reaching 89.3%, and the second dose of the meningitis B vaccine (MenB2) increased by 0.1%, achieving 91.5%. Thus, the escalating adoption of conjugate vaccines among adults is leading to the growth of the conjugate vaccine market.
What Key Areas Define The Segmentation Of The Global Conjugate Vaccine Market?
The conjugate vaccine market covered in this report is segmented –
1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines
2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines
Pre-Book The Conjugate Vaccine Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Conjugate Vaccine Market?
A significant trend emerging in the conjugate vaccine market is the innovative advancements occurring within it. To secure their market standing, corporations within the conjugate vaccine sector are striving towards creating advanced conjugate vaccines. For example, Pfizer Inc., an American pharmaceutical and biotech firm, introduced Prevnar 20 in Canada, a pneumococcal 20-valent conjugate vaccine aimed at preventing pneumonia and invasive pneumococcal infections amongst adults aged 18 and over, back in June 2022. Prevnar 20 represents an enhancement on its prior version, Prevnar 13, including conjugates for the original 13 serotypes as well as seven new ones specifically linked with invasive pneumococcal disease, increased incidence of fatalities, antimicrobial resistance, and meningitis.
Who Are the Key Players in the Conjugate Vaccine Market?
Major companies operating in the conjugate vaccine market include:
• Sanofi S.A.
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• Bharat Biotech International Limited
• Serum Institute of India Private Limited
• Biological E. Limited
• Bavarian Nordic A/S
• CSL Limited
• Novartis AG
• GreenSignal Bio Pharma Limited
• Taj Pharmaceuticals Limited
• Vaxcyte Inc.
• Neuron Biotech Co. Ltd.
• Bio-Med Pvt. Ltd.
• Sinovac Biotech Ltd.
• Takeda Pharmaceutical Company Limited
• Valneva SE
• Dynavax Technologies Corporation
• Emergent BioSolutions Inc.
• Hualan Biological Engineering Inc.
• Panacea Biotec Ltd.
• Protein Sciences Corporation
• Seqirus
What Is The Most Dominant Region In The Conjugate Vaccine Market?
North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
